The impact of onychomycosis on quality of life:: Development of an international onychomycosis-specific questionnaire to measure patient quality of life

被引:115
作者
Drake, LA
Patrick, DL
Fleckman, P
André, J
Baran, R
Haneke, E
Sapède, C
Tosti, A
机构
[1] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Hop Univ St Pierre, Dept Dermatol, B-1000 Brussels, Belgium
[4] Nail Dis Ctr, Cannes, France
[5] Klinikum Stadt Wuppertal, Wuppertal, Germany
[6] MAPI, Lyon, France
[7] Univ Bologna, Inst Clin Dermatol, I-40126 Bologna, Italy
关键词
D O I
10.1016/S0190-9622(99)70047-2
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 [皮肤病与性病学];
摘要
Background: Onychomycosis is a widespread refractory disease deleteriously affecting quality of life via social stigma and disrupting daily activities. Many physicians perceive onychomycosis as a cosmetic rather than a medical problem. Objective: Our purpose was to develop a questionnaire-based instrument to quantify the impact of onychomycosis on patients' quality of life. Methods: The questionnaire was developed and validated in a multinational cross-sectional study. Completed questionnaires from 532 patients were analyzed: 284 toenail, 248 fingernail (onychomycosis or paronychia). Results:The degree of quality of life impairment from onychomycosis varied by country studied, possibly reflecting cross-national health perception differences. Longer duration of disease, greater involvement of individual nails, and greater number of nails involved were associated with more serious adverse effects. Many physicians underestimated the associated degree of pain. Conclusion: The study confirms that onychomycosis physically and psychologically affects patients' lives. The questionnaire may be a valuable tool in evaluating the effect of therapeutic agents on quality of life of patients with onychomycosis.
引用
收藏
页码:189 / 196
页数:8
相关论文
共 19 条
[1]
[Anonymous], MED OUTCOMES TRUST B
[2]
DRAKE LA, 1995, CLIN COURIER, V13, P4
[3]
Update on the management of onychomycosis: Highlights of the third annual international summit on cutaneous antifungal therapy [J].
Elewski, BE ;
Hay, RJ .
CLINICAL INFECTIOUS DISEASES, 1996, 23 (02) :305-313
[4]
GONZALEZSERVA S, 1990, NAILS THERAPY DIAGNO, P11
[5]
HANEKE E, 1996, P 2 INT S ON FLOR IT, P12
[6]
QUALITY-OF-LIFE OF PERSONS WITH ONYCHOMYCOSIS [J].
LUBECK, DP ;
PATRICK, DL ;
MCNULTY, P ;
FIFER, SK ;
BIRNBAUM, J .
QUALITY OF LIFE RESEARCH, 1993, 2 (05) :341-348
[7]
Patrick DL., 1994, Quality of life assessment: International perspectives, P19
[8]
PATRICK DL, 1993, HLTH STATUS HLTH POL, P181
[9]
PREVALENCE OF DERMATOPHYTE ONYCHOMYCOSIS IN THE UNITED-KINGDOM - RESULTS OF AN OMNIBUS SURVEY [J].
ROBERTS, DT .
BRITISH JOURNAL OF DERMATOLOGY, 1992, 126 :23-27
[10]
ONYCHOMYCOSIS IS MORE THAN A COSMETIC PROBLEM [J].
SCHER, RK .
BRITISH JOURNAL OF DERMATOLOGY, 1994, 130 :15-15